A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that usually results in respiratory failure and death. Pirfenidone was approved as the first licensed therapy for IPF in Europe based on phase III trials where patients with a forced vital capacity (FVC) >50% o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sköld, Carl Magnus, Janson, Christer, Elf, Åsa Klackenberg, Fiaschi, Marie, Wiklund, Kerstin, Persson, Hans Lennart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Co-Action Publishing 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951637/
https://www.ncbi.nlm.nih.gov/pubmed/27435431
http://dx.doi.org/10.3402/ecrj.v3.32035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951637/
https://www.ncbi.nlm.nih.gov/pubmed/27435431
http://dx.doi.org/10.3402/ecrj.v3.32035

Ejemplares similares